

To: [redacted] [redacted] @rivm.nl]; [redacted] [redacted] @rivm.nl]; [redacted] [redacted] @rivm.nl]
From: [redacted] [redacted]
Sent: Wed 12/2/2020 6:28:27 PM
Subject: FW: Eurosurveillance editorial board newsletter
Received: Wed 12/2/2020 6:28:27 PM
[Eurosurv - Contributor Survey Report.pdf](#)
[Eurosurv - statistics.pdf](#)

Hoi,
 Jullie artikel over incubatietijd staat nr 4 meest bekeken artikel in Eurosurv!
 Groeten,

[redacted]

From: [redacted] [redacted] @rivm.nl>
Sent: dinsdag 17 november 2020 11:25
To: [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@rivm.nl>
Subject: Eurosurveillance editorial board newsletter

Hi [redacted] en [redacted]
 Ter info, ook de laatste statistieken van Eurosurveillance.
 Zag deze nog terugkomen in het sociale media overzicht.

Social media

Our social media continues to see good uptake and interaction. A recent Tweet that attracted a high number of readers to the website was for an article on [SARS-CoV-2 infection in farmed minks in the Netherlands](#).

Groetjes, [redacted]



Dear board members,

I hope this message finds you healthy and well despite the ongoing pandemic, which continues to demand much of everyone's attention and time.

The year 2020 marks the end of the *Eurosurveillance* long-term strategy, 2014–20. In preparation for our new strategy, covering 2021–27, we sought feedback from authors, reviewers and readers via a contributor survey in January. The results were generally positive and we also received good ideas for improvement. Together with the ECDC external evaluation, which attested *Eurosurveillance*'s added value for Europe, the survey results motivate us for the future.

In this newsletter, covering May to mid-November 2020, we present statistics, news and updates about the journal, our team and our activities, including highlights of our COVID-19 pandemic output. Maintaining good visibility among the tsunami of COVID-19 publications is very important for the continued success of *Eurosurveillance*. We count on you to act as our ambassadors and help us promote our articles whenever possible and suitable: at conferences, in your interactions with the media, via your social media channels and by encouraging your press teams.

With kind regards,

[redacted]



COVID-19 pandemic

Submissions

The majority of submissions continue to be on COVID-19; however, the total number has gone down slightly compared with the second quarter of 2020.

Collections

We have continued to update our [Coronavirus disease \(COVID-19\)](#) and [Children and COVID-19](#) collections, which are now up to 107 and 11 articles, respectively.

Rapid communications

Between May and August we ran a series of Rapid communications and an [editorial](#) on COVID-19 excess mortality, with contributions from [Italy](#), [England](#) and [France](#), as well as the EuroMOMO network's pooled early estimates for [Europe](#).

Reviewers

Despite the impact that the pandemic is having on experts' capacities, we have received tremendous support in the form of peer review of our COVID-19 submissions. We therefore published a short [thank you note](#) on the occasion of [Peer Review Week 2020](#), in which we named all of the reviewers that have aided us in publishing relevant public health information and evidence about the ongoing pandemic.



Statistics

Publishing


Here we present some summary statistics from 1 January to 31 October 2020, as compared with the same period in 2019. During this period there was high pressure on the team, indicated by a marked increase in submissions, while the output was kept stable. Additional statistics can be found in the attachment: 'Eurosurv – statistics.pdf'.

From 1 January to 31 October 2020 (compared with same period in 2019), we

- received **1,909** submissions (2019: 664)
817 rapid comms (2019: 167), 1,000 regular articles (2019: 470), 92 'other' (2019: 27)
- made **1,805** decisions (reject/remove/accept) (2019: 650)
805 rapid comms (2019: 176), 1,000 regular articles (2019: 474)
- had a rejection rate of **89%** (2019: 75%)
88% for rapid comms (2019: 69%), 90% for regular articles (2019: 77%)
- edited and published **201** articles (2019: 205)
100 rapids (2019: 55), 76 regular (2019: 134), 9 editorials, 16 letters
- had to publish **3** errata (2019: 3) and **17** author's correction (2019: 5)

Submissions

Our average submissions per month from 2013 to October 2020 are indicated in the figure below. Of note, we received around three times as many submissions this year. In particular, the number of rapid communications was five times higher compared with 2019.



Publishing

Special and focused issues

The journal's Point of Care Testing (POCT) special issue [part one](#) and [part two](#) have now been published, and a PDF is forthcoming. We are delighted that our 2019 [5.1.2e](#) and [5.1.2e](#) accepted our invitation to write the accompanying [editorial](#).

To give readers a break from COVID-19, we also recently published [a focused issue](#) for [World Rabies Day](#).

Of note

We recently published a rapid communication about the [first autochthonous dengue outbreak in Italy](#), followed by another on [two imported cases to the Netherlands from](#) [5.1.2a](#)

Contributor survey

In January we ran an online contributor survey that attracted 177 respondents. We also conducted seven in-depth interviews. These two pieces showed that *Eurosurveillance* is highly appreciated and seen as a credible and reliable

source of research that is used for public health action. Our authors also clearly appreciated the service we provide. For more information, please see the attached report, 'Eurosurg – Contributor Survey Report.pdf'; an editorial regarding these results will be published today.

Social media

Our social media continues to see good uptake and interaction. A recent Tweet that attracted a high number of readers to the website was for an article on [SARS-CoV-2 infection in farmed minks in the Netherlands](#).

Training and Capacity building

Ines represented *Eurosurveillance* at the EPIET/EUPHEM virtual project review module, facilitation and seminar on 25–27 August, where she acted as a moderator and facilitator, and gave a seminar on 'Improving your chances to get published'.

Appeals and complaints

During this period we received appeals regarding three articles that were rejected after peer review; these were resolved with the help of six board members. The final resolutions were to maintain our decisions to reject. Ethical concerns were also flagged for the article [Detection of 2019 novel coronavirus \(2019-nCoV\) by real-time RT-PCR](#); we consulted with experts on conflict of interest and research integrity, as well as associate editors, then amended the paper's conflict of interest statement and published an [editorial note](#).

Following a notification from the authors on 24 August of a computational error in their article, [Accounting for indirect protection in the benefit–risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018](#), an [expression of concern](#) was published on the same day. After re-evaluation of the corrected version by the original peer reviewers and confirmation from an associated editor that corrections do not impact the overall results and message/conclusions, we published an [authors' correction](#) on 1 October with an accompanying [editorial note](#) concluding that we revoke the note of concern.



Staff and board

News from the team

We are pleased to welcome back [REDACTED] and [REDACTED] and bid a farewell to [REDACTED] and [REDACTED]. [REDACTED] and [REDACTED] in a role focused on planning and implementing country support activities. We have also recently contracted a [REDACTED] who will edit a limited number of articles to help us maintain our output.

Submission of Declaration of Interests for 2021

The request and instructions to submit your 2021 Declaration of Interests via the electronic submission system will be sent out on 17 November. The submission deadline is 1 December 2020.

Board updates

5.1.2e

We are pleased to welcome a [5.1.2e] [5.1.2e], from the Ministry of Health of the Republic of Lithuania at Vilnius University in Vilnius.

We have also updated our compilation of [board member biographies](#), which is featured on the [Editorial board page](#) of our website.



Upcoming and recent activities

Annual Editorial Board Meeting, 4 December, 2020 (9:00–13:00 CET)

Following the three virtual consultation meetings that took place in October, we look forward to fruitful discussion at the virtual Annual Editorial Board Meeting in December. Official invitation, agenda and instructions for joining have been sent to you via email.

Editorial board virtual consultation meetings, 13, 15 and 20 October, 2020

Three virtual consultation meetings took place in October: 'Eurosurveillance and ECDC synergies' (13 Oct), 'Scope of Journal' (15 Oct) and 'Supplements/Preprints' (20 Oct). Summaries were sent to you via email and the results will be discussed at the virtual Annual Editorial Board Meeting.

[ESCMID Conference on Coronavirus Disease \(ECCVID\)](#), 23–25 September, 2020

ECCVID covered all aspects of COVID-19 and featured a comprehensive scientific programme, including a meet-the-expert session 'How to generate evidence for pandemic response,' co-presented by Ines.

[European Association of Science Editors \(EASE\) Virtual Conference](#), 12 June, 2020

EASE hosted its first virtual conference on Friday, 12 June 2020 on the theme 'editors and editing in times of crisis'. Ines delivered the opening address and served as moderator of the first plenary.

Do you have any ideas for new activities, thoughts on our operations or feedback regarding the board newsletter? Let us know: [5.1.2e] [\[5.1.2e\]@ecdc.europa.eu](mailto:[5.1.2e]@ecdc.europa.eu)

Follow us on social



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.